Overview

A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis

Status:
Active, not recruiting
Trial end date:
2023-01-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company